Boston Scientific/$BSX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Ticker

$BSX
Sector

Primary listing

NYSE

Employees

53,000

BSX Metrics

BasicAdvanced
$149B
59.83
$1.68
0.66
-

What the Analysts think about BSX

Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.

Bulls say / Bears say

BSX raised its 2025 adjusted profit forecast to $2.95–$2.99 per share and trimmed the estimated tariff headwind to $100 million, reflecting confidence in offsetting cost pressures through robust sales growth and operational leverage (Reuters).
Boston Scientific reported Q2 adjusted EPS of $0.75 on revenue of $5.06 billion, beating analyst estimates and driven by strong demand for its Farapulse and Watchman heart rhythm devices (Reuters).
In Q2, the cardiovascular unit generated $3.34 billion in sales, underscoring the strength of BSX’s interventional cardiology portfolio and sustained market leadership in core growth segments (Reuters).
Early Alert: the FDA warned on August 6, 2025 that certain ENDOTAK RELIANCE defibrillation leads with calcified ePTFE‐coated coils have been linked to 386 serious injuries and 16 deaths, prompting recommendations for early replacement and posing significant safety and legal risks (FDA).
Recall: on July 7, 2025 Boston Scientific issued a removal letter for the Carotid WALLSTENT Monorail Endoprosthesis due to a manufacturing defect causing resistance upon device withdrawal, with six reported cases requiring additional interventions and potential stroke risk (FDA).
Product setback: on May 28, 2025 BSX halted global sales of its Acurate neo2 and Acurate Prime TAVR systems and will not pursue further regulatory approvals due to prohibitive requirements, marking a retreat from the structural heart market and potential revenue loss in that growth segment (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

BSX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BSX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BSX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs